Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [28][29] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the prior year [29] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30] - Non-GAAP net income for Q4 2025 was $160 million or $1.34 per diluted share, compared to $149 million or $1.19 per diluted share in the prior year [31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - International dental merchandise sales grew by 9.2%, driven by growth across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - Global specialty products group sales increased by 14.6%, with strong performance in implants and biomaterials, particularly in Germany, Brazil, and France [22][33] Market Data and Key Metrics Changes - U.S. medical distribution sales grew by 4.9%, reflecting strong growth in home solutions, while international dental equipment sales grew by 13.9% [32][33] - The U.S. dental market showed signs of stability and positive trends, with patient traffic remaining stable and a slight positive lean observed [15][51] - International equipment sales growth was broad-based, benefiting from currency exchange rates [21] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [11] - Significant progress has been made in rolling out the global e-commerce platform, henryschein.com, and partnerships with Amazon Web Services for AI integration [12][26] - The company aims to achieve over $200 million in operating income improvement through value creation initiatives, including cost savings and capturing incremental gross margin opportunities [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the U.S. dental market and the positive sentiment among dentists regarding investments in new technologies [51] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to the timing of value creation initiatives [58] - Management noted that the overall market for dental implants is stable, with positive momentum in international markets, particularly in Germany [72] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [35] - Operating cash flow for Q4 2025 was $381 million, compared to $204 million in Q4 2024, driven by effective working capital management [36] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from the $125 million run rate will be more heavily weighted to the back half of the year, with some lumpiness expected in the quarters [41][42] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases observed [45][48] Question: Durability of market performance - Management confirmed that the U.S. dental market is stable and leaning positively, with good feelings among dentists about investing in new technologies [50][51] Question: Sustainability of implant performance - Management expressed optimism about the sustainability of implant performance, particularly in international markets, while noting that U.S. growth is more stable but less robust [67][72]
Henry Schein(HSIC) - 2025 Q4 - Earnings Call Transcript